Medication info
Erosuvab 5 mg Tablet (Rosuvastatin Calcium (unrefined))

Erosuvab 5 mg Tablet (Rosuvastatin Calcium (unrefined))

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium Micronized›5.2mg / 1 tablet
Manufacturer / importer
Jungheon Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 201906517 · Approved 2019.09.18 · Insurance code 053301010

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and reduction of cardiovascular risk
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, up to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (10 to 17 years of age) The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.

Ingredients

Manufacturer
Jungheon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and reduction of cardiovascular risk

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • atherosclerosis
  • heterozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
View approved original text

This medication is primarily used in various conditions associated with hypercholesterolemia. In patients with primary hypercholesterolemia or mixed dyslipidemia where dietary and exercise management alone is inadequate, it is used as an adjunct to dietary therapy. Additionally, it is employed as an adjunct in patients with homozygous familial hypercholesterolemia alongside dietary therapy or other lipid-lowering treatments. In patients with hypercholesterolemia, it helps lower total cholesterol and LDL-cholesterol levels to target goals, thereby delaying the progression of atherosclerosis. For pediatric patients with heterozygous familial hypercholesterolemia, where cholesterol levels remain high despite dietary intervention, it is also used as an adjunct. Furthermore, it is effective as an adjunct to dietary therapy in patients with primary dysbetalipoproteinemia. Lastly, it aids in reducing the risk of major cardiovascular events such as stroke and myocardial infarction in middle-aged individuals at risk for cardiovascular diseases. Overall, this medication is utilized for cholesterol control and reducing the risk of cardiovascular diseases.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, up to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (10 to 17 years of age) The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.

Precautions

This medication should not be administered to certain patients. For instance, patients with allergies to the ingredients of this medication, those with severely impaired liver function, those with muscle disorders, patients with significantly reduced kidney function, pregnant or breastfeeding women, and fertile women not using appropriate contraception should not take this medication. Moreover, high dosing of this medication is prohibited for patients at high risk of muscle-related side effects. Patients with risk factors such as genetic muscle disorders, hypothyroidism, or alcohol abuse should be particularly cautious. This medication contains lactose and should not be used by patients with lactose intolerance or certain genetic digestive disorders. Patients with a history of liver disease or excessive alcohol consumption should have regular liver function tests while using this medication, and patients with hyperlipidemia due to thyroid dysfunction or nephrotic syndrome must first treat the underlying cause. If symptoms such as myalgia, muscle weakness, or cramps occur, the patient should immediately inform their doctor and undergo necessary tests; in severe cases, discontinuation of the medication may be necessary. This medication may rarely cause serious skin reactions, liver damage, kidney abnormalities, and neurological symptoms in some patients, so immediate consultation with healthcare professionals is advised if such symptoms develop. Additionally, this medication may interact with several other drugs; therefore, patients should inform healthcare professionals about any other medications they are taking, especially when combined with certain antivirals, immunosuppressants, antifungals, some antibiotics, and fibrate drugs. Women who are pregnant or might become pregnant must ensure appropriate contraception and should stop taking this medication immediately if pregnancy is confirmed. In the event of overdose, as no specific antidote exists, treatment must be symptomatic, and liver function and muscle enzyme tests are necessary. This medication does not appear to significantly affect the ability to drive or operate machinery; however, caution is advised due to potential dizziness. Finally, this medication may show higher blood concentrations in Asians, thus dosage adjustments may be necessary.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculobulbar weakness, thrombocytopenia, jaundice, hepatitis, elevated transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, elevated ALT, chest pain, elevated CK, elevated AST, joint pain, fatigue, numbness, sensory disturbances, chest discomfort, anorexia, abdominal distension, abnormal liver function tests, syncope, systemic pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature in the range of 1 to 30 degrees Celsius. Proper storage will help maintain the efficacy and safety of the medication.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.